Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 22;17(5):62.
doi: 10.3390/neurolint17050062.

Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice

Takafumi Tanei  1   2 , Shun Yamamoto  1 , Satoshi Maesawa  1   3 , Yusuke Nishimura  1 , Tomotaka Ishizaki  1 , Yoshitaka Nagashima  1 , Yoshiki Ito  1 , Miki Hashida  1 , Takahiro Suzuki  1 , Hajime Hamasaki  1 , Toshihiko Wakabayashi  2 , Ryuta Saito  1
Affiliations

Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice

Takafumi Tanei et al. Neurol Int. .

Abstract

Background/Objectives: Lasmiditan is a newly developed drug for the acute treatment of migraine attacks, but factors associated with its efficacy remain unclear. This study aimed to confirm the efficacy of lasmiditan started at 50 mg under various dosing conditions and identify factors associated with its efficacy. Methods: There are four reasons for prescribing lasmiditan: as an add-on to triptan, if triptan is ineffective, if triptan produces side effects, and when triptan is contraindicated. Lasmiditan was administered at a dose of 50 mg. The efficacy of lasmiditan was defined as the disappearance of headache or a 50% or greater reduction in headache intensity within two hours after dosing. This study included 108 patients with migraines who took lasmiditan. Results: The results for efficacy and the side effects of lasmiditan were as follows: effective without side effects (22), effective with mild side effects (32), ineffective (14), and severe side effects (40). The efficacy rate of lasmiditan 50 mg was 50.0% (54/108). The following factors were found to be associated with lasmiditan's efficacy: sex, migraine classification, calcium channel blockers, and anti-calcitonin gene-related peptide monoclonal antibody (CGRP-mAb) treatment. The overall incidence of side effects was 66.7%, and the dropout rate was 37.0%. Somnolence was more prevalent in the effective group, and other side effects were more prevalent in patients who dropped out due to the side effects of lasmiditan. Conclusions: Lasmiditan is likely to be effective in males with severe migraine classification and receiving CGRP-mAb treatment. If mild somnolence is a side effect, the drug can be continued and may be effective.

Keywords: 50 mg; lasmiditan; migraine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flowchart showing patient selection.
Figure 2
Figure 2
Flowchart showing efficacy and side effects of lasmiditan. w: with, wo: without.
See this image and copyright information in PMC

References

    1. Ashina M., Katsarava Z., Do T.P., Buse D.C., Pozo-Rosich P., Özge A., Krymchantowski A.V., Lebedeva E.R., Ravishankar K., Yu S., et al. Migraine: Epidemiology and systems of care. Lancet. 2021;397:1485–1495. doi: 10.1016/S0140-6736(20)32160-7. - DOI - PubMed
    1. Raggi A., Leonardi M., Arruda M., Caponnetto V., Castaldo M., Coppola G., Della Pietra A., Fan X., Garcia-Azorin D., Gazerani P., et al. Hallmarks of primary headache: Part 1—Migraine. J. Headache Pain. 2024;25:189. doi: 10.1186/s10194-024-01889-x. - DOI - PMC - PubMed
    1. Shimizu T., Sakai F., Miyake H., Sone T., Sato M., Tanabe S., Azuma Y., Dodick D.W. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J. Headache Pain. 2021;22:29. doi: 10.1186/s10194-021-01243-5. - DOI - PMC - PubMed
    1. Goadsby P.J., Reuter U., Hallström Y., Broessner G., Bonner J.H., Zhang F., Sapra S., Picard H., Mikol D.D., Lenz R.A. A Controlled Trial of Erenumab for Episodic Migraine. N. Engl. J. Med. 2017;377:2123–2132. doi: 10.1056/NEJMoa1705848. - DOI - PubMed
    1. Skljarevski V., Matharu M., Millen B.A., Ossipov M.H., Kim B.K., Yang J.Y. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38:1442–1454. doi: 10.1177/0333102418779543. - DOI - PubMed

LinkOut - more resources